RTI Surgical, a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic, and metal implants, has entered in a long-term strategic agreement with leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.
As part of the agreement, RTI Surgical has acquired Exactech’s Optecure®, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities. Optecure® will complement RTI Surgical’s market-leading portfolio of bone graft substitutes.
Biologic materials that support joint replacement surgery are an important facet of Exactech’s business. This collaboration with RTI allows each company to focus on our unique strengths.
Having a partner like Exactech trust us to become a preferred supplier for their bone graft portfolio is a key milestone in our journey to become the market-leading private-label implant supplier to OEMs.
Optecure® is RTI Surgical’s first product acquisition since the company was acquired by Montagu in 2020.
For more information, visit www.rtisurgical.com